Brief: Transcode Therapeutics Gets Nasdaq Minimum Bid Price Deficiency Letter
16/08/2024 22:22
Aug 16 (Reuters) - Transcode Therapeutics Inc RNAZ.O :
* TRANSCODE THERAPEUTICS: ON AUGUST 13, GOT NOTICE OF
DELISTING OR
FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD
Source text for Eikon: ID:n0001104659-24-090559
Further company coverage: RNAZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors